登革熱國際期刊學術論文免費下載(part II) 人氣: 995
2015-10-28
登革熱案例分享
Assessing the epidemiological effect of wolbachia for dengue control
The Lancet Infectious Diseases, 2015-07-01, Volume 15, Issue 7, Pages 862-866
Dengue viruses cause more human morbidity and mortality than any other arthropod-borne virus. Dengue prevention relies mainly on vector control; however, the failure of traditional methods has promoted the development of novel entomological approaches. Although use of the intracellular bacterium wolbachia to control mosquito populations was proposed 50 years ago, only in the past decade has its use as a potential agent of dengue control gained substantial interest. Here, we review evidence that supports a practical approach for dengue reduction through field release of wolbachia-infected mosquitoes and discuss the additional studies that have to be done before the strategy can be validated and implemented. We therefore present a pragmatic approach to acquiring preliminary evidence of efficacy through various complementary methods including a prospective cohort study, a geographical cluster investigation, virus phylogenetic analysis, virus surveillance in mosquitoes, and vector competence assays. This multipronged approach could provide valuable intermediate evidence of efficacy to justify a future cluster randomized trial.
 
Epidemiologic characteristics of dengue in China (2010–2014)
Journal of Infection, 2015-09-01, Volume 71, Issue 3, Pages 397-399
Our data analysis showed that 53,743 cases of dengue were reported in China from 2010 to 2014. Among these cases, 49.66% occurred in males and 50.34% occurred in females. No deaths occurred from 2010 to 2013, whereas six deaths occurred in 2014. From 2010 to 2013, most cases (64.31%) involved individuals aged 20-49 years (20-29 years: 23.44%; 30-39years: 20.89%; 40-49years: 19.98%), whereas 2.80%, 8.62%, 11.66%, and 12.61% of cases occurred in individuals aged 0-9, 10-19, 50-59, and over 60 years,
respectively. Surprisingly, in 2014, the dengue infection rate increased by 1.52% in individuals aged 0e9 years and 4.87% in individuals over 60 years. But the 20-49 year age group still remained the most heavily affected.

 
Knowledge, attitudes and preventive behaviors related to dengue vector breeding control measures among adults in communities of Vientiane, capital of the Lao PDR
Journal of Infection and Public Health, 2015-09-01, Volume 8, Issue 5, Pages 466-473
This research aimed to determine the knowledge, attitudes and preventive behaviors (KAP) of adults in relation to dengue vector control measures in the communities of Vientiane, the capital of the Lao PDR. A total of 207 respondents were actively participating in this cross-sectional descriptive study in 2011. Representatives of households were interviewed face-to-face by six trained inter-viewers using a structured questionnaire. KAP reliabilities of 0.89, 0.91 and 0.95were reported in the pilot sample of 30 cases. The results revealed that 51.69% of the respondents had a high level of knowledge. More than 94% of the respondents knew that dengue fever is a dangerous communicable disease and that dengue fever is transmitted from person to person via mosquitoes. More than half (56.52%) of the participants had positive attitudes toward vector control measures, and 52.17% exhibited a high level of preventive behavior in terms of dengue vector control measures.
 
Vertical transmission of dengue fever: First case reported in Taiwan
Journal of the Formosan Medical Association, 2015-06-01, Volume 114, Issue 6, Pages 558-559
A full-term female newborn (gestational age, 40 weeks; birth body weight, 2986 g) was admitted to our neonatal intensive care unit (NICU) due to respiratory distress in July 2014. Her mother had suffered from fever with general weakness 5 days before delivery. Dengue fever was diagnosed
2 days before delivery by the Centers for Disease Control and Prevention (CDC), Taiwan. The neonate was delivered by emergency cesarean section due to fetal distress, and slight dyspnea and cyanosis were noted due to meconium aspiration syndrome. After admission to our NICU, her respiratory distress gradually improved.


登革熱疫苗
Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: A randomised study
Vaccine, 2015-09-22, Volume 33, Issue 39, Pages 5127-5134
Phase III lots can be produced in a consistent manner with predictable immune response and acceptable safety profile similar to previously characterised phase II lots. The phase III lots may be considered as not clinically different as statistical equivalence was shown for serotypes 1, 3 and 4 across the phase III lots. For serotype 2, although equivalence was not shown between two lots, the GMTs observed in the phase III lots were consistently higher than those for the phase II lot. As such, in our view, biological equivalence for all serotypes was demonstrated.

The dengue vaccine pipeline: Implications for the future of dengue control
Vaccine, 2015-06-26, Volume 33, Issue 29, Pages 3293-3298
Dengue has become the most rapidly expanding mosquito-borne infectious disease on the planet, surpassing malaria and infecting at least 390 million people per year. There is no effective treatment for dengue illness other than supportive care, especially for severe cases. Symptoms can be mild or life threatening as in dengue hemorrhagic fever and dengue shock syndrome. Vector control has been only partially successful in decreasing dengue transmission. The potential use of safe and effective tetravalent dengue vaccines is an attractive addition to prevent disease or minimize the possibility of epidemics. There are currently no licensed dengue vaccines. This review summarizes the current status of all dengue vaccine candidates in clinical evaluation. Currently five candidate vaccines are in human clinical trials. One has completed two Phase III trials, two are in Phase II trials, and three are in Phase I testing.

Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates
Vaccine, 2015-08-07, Volume 33, Issue 33, Pages 4105-4116
We describe here the preclinical development of a dengue vaccine composed of recombinant subunit carboxy-truncated envelope (E) proteins (DEN-80E) for each of the four dengue serotypes. Immunogenicity and protective efficacy studies in Rhesus monkeys were conducted to evaluate monovalent and tetravalent DEN-80E vaccines formulated with ISCOMATRIX™ adjuvant. Our studies indicated that a 0, 1, 2 and 6 month vaccination schedule is superior to the 0, 1, and 2 month schedule in terms of durability. Overall, the subunit vaccine was demonstrated to induce strong neutralization titers resulting in protection against viremia following challenge even 8-12 months after the last vaccine dose.

Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia
Vaccine, 2015-07-17, Volume 33, Issue 31, Pages 3746-3751
We find that the responses to CYD-TDV are principally predicted by the baseline immunological status against DENV, but the trial is also a significant predictor. We find that the CYD-TDV vaccine generates similar titres against all serotypes following the third dose, though DENV4 is immunodominant after the first dose. This study contributes to a better understanding of the immunological responses elicited by CYD-TDV. The recent availability of phase-3 data is a unique opportunity to further investigate the immunogenicity and efficacy of the CYD-TDV vaccine, especially in subjects with different levels of pre-existing immunity against DENV.

Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope
Published July 30, 2015. Volume162, Issue3; Pages493-504
Dengue is the most common vector-borne viral disease, causing nearly 400 million infections yearly. Currently there are no approved therapies. Antibody epitopes that elicit weak humoral responses may not be accessible by conventional B cell panning methods. To demonstrate an alternative strategy to generating a therapeutic antibody, we employed a non-immuno dominant, but functionally relevant, epitope in domain III of the E protein, and engineered by structure-guided methods an antibody directed to it. The resulting antibody, Ab513, exhibits high-affinity binding to, and broadly neutralizes, multiple genotypes within all four serotypes. To assess therapeutic relevance of Ab513, activity against important human clinical features of dengue was investigated. Ab513 mitigates thrombocytopenia in a humanized mouse model, resolves vascular leakage, reduces viremia to nearly undetectable levels, and protects mice in a maternal transfer model of lethal antibody-mediated enhancement. The results demonstrate that Ab513 may reduce the public health burden from dengue.



全球醫藥新知網站
11158 台北市士林區德行西路40 號1 樓
1F, No. 40, Dexing W. Road, Shilin Dist., Taipei 11158, Taiwan
Tel: +886-2-7725-3624
Fax: +886-2-2833-9600
Email: service@globalmednews.com
© 2017 全球醫藥新知 All rights reserved

 全球醫藥新知網站使用條款與條件

 瀏覽人數: 4081270  人

頂控科技網頁設計公司 | 嚮應式網頁布局 | 網站製作